|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
JP5876637B2
(ja)
|
2006-10-18 |
2016-03-02 |
マリーナ バイオテック，インコーポレイテッド |
ニックまたはギャップの入った核酸分子およびそれらの使用
|
|
KR101629017B1
(ko)
*
|
2007-05-22 |
2016-06-10 |
아크투루스 쎄라퓨틱스, 인크. |
히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체
|
|
US20100015708A1
(en)
*
|
2008-06-18 |
2010-01-21 |
Mdrna, Inc. |
Ribonucleic acids with non-standard bases and uses thereof
|
|
EP2315831A2
(en)
*
|
2008-08-05 |
2011-05-04 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
|
|
WO2010045512A2
(en)
*
|
2008-10-16 |
2010-04-22 |
Mdrna , Inc. |
Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
|
|
CA2744093A1
(en)
|
2008-12-03 |
2010-06-10 |
Marina Biotech, Inc. |
Una oligomer structures for therapeutic agents
|
|
KR20120128598A
(ko)
|
2009-11-04 |
2012-11-27 |
마리나 바이오테크, 인크. |
활성 생성 전달 분자들
|
|
MX339050B
(es)
|
2009-12-18 |
2016-05-09 |
Novartis Ag |
Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
|
|
EP3214174B1
(en)
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
|
|
WO2011133584A2
(en)
*
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
|
WO2011133876A2
(en)
*
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
EP3061824B1
(en)
|
2010-04-23 |
2018-08-29 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-enac-related diseases
|
|
WO2011139842A2
(en)
*
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
|
EP2591106A1
(en)
|
2010-07-06 |
2013-05-15 |
InteRNA Technologies B.V. |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
CA2817218C
(en)
|
2010-11-10 |
2020-02-18 |
Nigel L. Webb |
Nuclions and ribocapsids
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
CN102719434A
(zh)
*
|
2011-03-31 |
2012-10-10 |
百奥迈科生物技术有限公司 |
抑制rna干扰脱靶效应的特异性修饰
|
|
WO2013030778A2
(en)
|
2011-09-02 |
2013-03-07 |
Novartis Ag |
Organic compositions to treat hsf1-related diseases
|
|
US10174314B2
(en)
|
2011-12-22 |
2019-01-08 |
Interna Technologies B.V. |
MiRNA for treating head and neck cancer
|
|
WO2013105022A2
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
EA201492004A1
(ru)
|
2012-05-02 |
2015-08-31 |
Новартис Аг |
Органические композиции для лечения kras-ассоциированных заболеваний
|
|
EP2917348A1
(en)
|
2012-11-06 |
2015-09-16 |
InteRNA Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
|
US9868949B2
(en)
|
2013-02-28 |
2018-01-16 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat EPAS1-related diseases
|
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
|
AU2014306416B2
(en)
*
|
2013-08-16 |
2021-02-25 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating RNA
|
|
CN109536493A
(zh)
|
2013-10-02 |
2019-03-29 |
阿尔尼拉姆医药品有限公司 |
用于抑制lect2基因表达的组合物和方法
|
|
WO2015050871A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compounds to treat hepatitis b virus
|
|
US10119143B2
(en)
|
2013-10-04 |
2018-11-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
WO2015051135A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compositions to treat hepcidin-related diseases
|
|
WO2015051044A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
|
US9988627B2
(en)
|
2013-10-04 |
2018-06-05 |
Novartis Ag |
Formats for organic compounds for use in RNA interference
|
|
WO2015051045A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
3'END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE
|
|
KR102736538B1
(ko)
|
2013-12-12 |
2024-12-03 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 ｉＲＮＡ 조성물 및 이의 이용 방법
|
|
WO2015123264A1
(en)
|
2014-02-11 |
2015-08-20 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
US9856475B2
(en)
|
2014-03-25 |
2018-01-02 |
Arcturus Therapeutics, Inc. |
Formulations for treating amyloidosis
|
|
CN106460025A
(zh)
|
2014-03-25 |
2017-02-22 |
阿克丘勒斯治疗公司 |
在基因沉默中具有降低的脱靶效应的una寡聚物
|
|
EP3122365B1
(en)
|
2014-03-25 |
2023-05-03 |
Arcturus Therapeutics, Inc. |
Transthyretin allele selective una oligomers for gene silencing
|
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
|
CN106574268B
(zh)
|
2014-05-22 |
2021-02-05 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原（AGT）iRNA组合物及其使用方法
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
EP3169784B1
(en)
|
2014-07-16 |
2020-06-10 |
Arrowhead Pharmaceuticals, Inc. |
Rnai compositions to treat apoc3-related diseases
|
|
WO2016010840A1
(en)
|
2014-07-16 |
2016-01-21 |
Novartis Ag |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
BR112017006679A2
(pt)
|
2014-10-02 |
2017-12-26 |
Protiva Biotherapeutics Inc |
moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
CA2966527C
(en)
*
|
2014-11-02 |
2024-02-06 |
Arcturus Therapeutics, Inc. |
Messenger una molecules and uses thereof
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
EP3221451A1
(en)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
AU2016219263B2
(en)
|
2015-02-13 |
2022-12-01 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
|
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
EP3277289A4
(en)
*
|
2015-04-01 |
2018-12-05 |
Arcturus Therapeutics, Inc. |
Therapeutic una oligomers and uses thereof
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
US20170016000A1
(en)
|
2015-07-17 |
2017-01-19 |
Arcturus Therapeutics, Inc. |
Compositions and agents against hepatitis b virus and uses thereof
|
|
WO2017015671A1
(en)
|
2015-07-23 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions for treating amyloidosis
|
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
EP3344769B1
(en)
|
2015-09-02 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
|
|
EP3353298B1
(en)
*
|
2015-09-21 |
2023-09-13 |
Arcturus Therapeutics, Inc. |
Allele selective gene editing and uses thereof
|
|
IL259795B2
(en)
|
2015-12-07 |
2024-04-01 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
KR102426487B1
(ko)
|
2016-06-06 |
2022-07-27 |
애로우헤드 파마슈티컬스 인코포레이티드 |
5'-시클로-포스포네이트 변형된 뉴클레오티드
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
MX2018016389A
(es)
|
2016-06-30 |
2019-08-16 |
Arbutus Biopharma Corp |
Composiciones y metodos para suministro de arn mensajero.
|
|
IL291323B2
(en)
|
2016-07-15 |
2023-09-01 |
Am Chemicals Llc |
Solid non-nucleoside supports and phosphoramidite building blocks for oligonucleotide synthesis
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
CA3045045A1
(en)
|
2017-01-10 |
2018-07-19 |
Zhen Li |
Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
|
|
EP3651852A1
(en)
|
2017-07-10 |
2020-05-20 |
Genzyme Corporation |
Methods and compositions for treating a bleeding event in a subject having hemophilia
|
|
EP3681516A4
(en)
|
2017-09-11 |
2021-09-29 |
Arrowhead Pharmaceuticals, Inc. |
RNAI AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)
|
|
CN111655268B
(zh)
|
2017-10-04 |
2024-03-26 |
艾维迪提生物科学公司 |
核酸-多肽组合物及其用途
|
|
WO2019086603A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
MX2020006012A
(es)
|
2017-12-18 |
2020-09-14 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de la caja 1 del grupo de alta movilidad (hmgb1) y métodos de uso de las mismas.
|
|
JP2021513508A
(ja)
|
2018-02-12 |
2021-05-27 |
インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． |
抗がんマイクロｒｎａ及びその脂質製剤
|
|
US12083224B2
(en)
|
2018-03-30 |
2024-09-10 |
Arcturus Therapeutics, Inc. |
Lipid particles for nucleic acid delivery
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
|
|
EP3833397A4
(en)
|
2018-08-08 |
2023-06-14 |
Arcturus Therapeutics, Inc. |
COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
AU2019321375A1
(en)
|
2018-08-13 |
2021-03-11 |
Alnylam Pharmaceuticals, Inc. |
Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
|
|
US11987792B2
(en)
|
2018-08-16 |
2024-05-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
EP3843845A4
(en)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
|
|
CA3105385A1
(en)
|
2018-09-18 |
2020-03-26 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
|
CN113613661B
(zh)
|
2019-01-09 |
2025-11-14 |
箭头药业股份有限公司 |
用于抑制HIF-2α(EPAS1)的表达的RNAi试剂、其组合物和使用方法
|
|
AU2020209186A1
(en)
|
2019-01-16 |
2021-09-09 |
Genzyme Corporation |
Serpinc1 iRNA compositions and methods of use thereof
|
|
US12215382B2
(en)
|
2019-03-01 |
2025-02-04 |
The General Hospital Corporation |
Liver protective MARC variants and uses thereof
|
|
US11578090B2
(en)
|
2019-06-06 |
2023-02-14 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
WO2020247818A1
(en)
*
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP2022546570A
(ja)
|
2019-09-03 |
2022-11-04 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｌｅｃｔ２遺伝子の発現を阻害するための組成物および方法
|
|
WO2021044004A1
(en)
*
|
2019-09-05 |
2021-03-11 |
Sanofi |
Oligonucleotides containing nucleotide analogs
|
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
CN115176004A
(zh)
|
2019-10-22 |
2022-10-11 |
阿尔尼拉姆医药品有限公司 |
补体成分C3 iRNA组合物及其使用方法
|
|
CA3155921A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
IL293824A
(en)
|
2019-12-13 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them
|
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
CN115427571A
(zh)
|
2020-02-10 |
2022-12-02 |
阿尔尼拉姆医药品有限公司 |
沉默vegf-a表达的组合物和方法
|
|
CA3171654A1
(en)
|
2020-02-18 |
2021-08-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
JP2023516095A
(ja)
|
2020-03-06 |
2023-04-17 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法
|
|
EP4121534A1
(en)
|
2020-03-18 |
2023-01-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
EP4127168A1
(en)
|
2020-03-26 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
JP2023520582A
(ja)
|
2020-04-06 |
2023-05-17 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｍｙｏｃ発現をサイレンシングするための組成物および方法
|
|
EP4133079A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
CN115955972A
(zh)
|
2020-04-27 |
2023-04-11 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白E(APOE)iRNA剂组合物及其使用方法
|
|
KR20230017789A
(ko)
|
2020-04-30 |
2023-02-06 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
EP4162033A4
(en)
|
2020-06-09 |
2024-12-25 |
Alnylam Pharmaceuticals, Inc. |
Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
|
|
BR112022024420A2
(pt)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
|
|
TW202227102A
(zh)
|
2020-09-22 |
2022-07-16 |
瑞典商阿斯特捷利康公司 |
治療脂肪肝病之方法
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
MX2023005490A
(es)
|
2020-11-13 |
2023-05-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) del factor de coagulacion v (f5) y sus metodos de uso.
|
|
WO2022125490A1
(en)
|
2020-12-08 |
2022-06-16 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
AU2022220704A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
|
|
BR112023016645A2
(pt)
|
2021-02-26 |
2023-11-14 |
Alnylam Pharmaceuticals Inc |
Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
|
|
IL305414A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
EP4314296A2
(en)
|
2021-03-29 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
WO2022231999A1
(en)
|
2021-04-26 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
WO2022256290A2
(en)
|
2021-06-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
|
EP4373933A1
(en)
|
2021-07-23 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
JP2024529437A
(ja)
|
2021-07-29 |
2024-08-06 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
|
|
KR20240042004A
(ko)
|
2021-08-03 |
2024-04-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물 및 이의 사용 방법
|
|
KR20240042016A
(ko)
|
2021-08-04 |
2024-04-01 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(AGT)을 침묵화하기 위한 iRNA 조성물 및 방법
|
|
JP2024534766A
(ja)
|
2021-08-13 |
2024-09-26 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法
|
|
MX2024002440A
(es)
|
2021-08-31 |
2024-03-08 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
|
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
US12042509B2
(en)
|
2021-10-01 |
2024-07-23 |
Adarx Pharmaceuticals, Inc. |
Prekallikrein-modulating compositions and methods of use thereof
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
|
|
AU2022421244A1
(en)
|
2021-12-22 |
2024-07-11 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
EP4536831A2
(en)
|
2022-06-10 |
2025-04-16 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
|
JP2025527531A
(ja)
|
2022-08-18 |
2025-08-22 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
|
|
MA71735A
(fr)
|
2022-09-15 |
2025-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|
|
EP4627084A1
(en)
|
2022-12-01 |
2025-10-08 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
EP4662311A2
(en)
|
2023-02-09 |
2025-12-17 |
Alnylam Pharmaceuticals, Inc. |
Reversir molecules and methods of use thereof
|
|
KR20250174651A
(ko)
|
2023-04-06 |
2025-12-12 |
상하이 아르고 바이오파마슈티칼 씨오., 엘티디. |
5'-포스포네이트 변형 뉴클레오시드 유사체 및 이로부터 제조된 올리고뉴클레오티드
|
|
AU2024258561A1
(en)
|
2023-04-20 |
2025-10-30 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024238396A1
(en)
|
2023-05-12 |
2024-11-21 |
Adarx Pharmaceuticals, Inc. |
Nmda ligand conjugated compounds and uses thereof
|
|
CN119836430A
(zh)
*
|
2023-05-12 |
2025-04-15 |
北京炫景瑞医药科技有限公司 |
修饰的核苷类似物及其用途与含核苷酸类似物的双链寡核苷酸及其用途
|
|
AU2024279767A1
(en)
|
2023-05-26 |
2025-12-04 |
Adarx Pharmaceuticals, Inc. |
Sod1-modulating compositions and methods of use thereof
|
|
WO2024263694A1
(en)
|
2023-06-20 |
2024-12-26 |
Adarx Pharmaceuticals, Inc. |
Lrrk2-modulating compositions and methods of use thereof
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
WO2025024334A1
(en)
|
2023-07-21 |
2025-01-30 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
Ｃａｓ內切酶及相關方法
|
|
WO2025024493A1
(en)
|
2023-07-25 |
2025-01-30 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
GB202314724D0
(en)
|
2023-09-26 |
2023-11-08 |
Astrazeneca Ab |
compounds and methods for reducing psd3 expression
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072713A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Polymyxins for delivery of agents to the kidney
|
|
WO2025072672A2
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Slc6a19-targeting modulatory nucleic acid agents
|
|
WO2025072699A1
(en)
|
2023-09-27 |
2025-04-03 |
Judo Bio, Inc. |
Aminoglycosides for delivery of agents to the kidney
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|
|
WO2025096809A1
(en)
|
2023-10-31 |
2025-05-08 |
Korro Bio, Inc. |
Oligonucleotides comprising phosphoramidate internucleotide linkages
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
WO2025140551A1
(en)
|
2023-12-29 |
2025-07-03 |
Neuro3 Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS
|
|
WO2025178854A2
(en)
|
2024-02-19 |
2025-08-28 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting cideb and related methods
|
|
US20250313840A1
(en)
|
2024-03-20 |
2025-10-09 |
Vertex Pharmaceuticals Incorporated |
Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025255388A1
(en)
|
2024-06-05 |
2025-12-11 |
Camp4 Therapeutics Corporation |
Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
|
|
WO2025259747A2
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
|
|
WO2025259743A1
(en)
|
2024-06-12 |
2025-12-18 |
Alnylam Pharmaceuticals, Inc. |
Dual conjugate compounds for extrahepatic delivery
|
